Effectiveness and Safety of Whitfield's Solution, Zinc Oxide Nanoparticles Solution or Combination for the Treatment of Fungal Feet Infection (WhitfieldZinc)
Fungal Foot Infection
About this trial
This is an interventional treatment trial for Fungal Foot Infection focused on measuring Whitfield, Zinc oxide nanoparticles, Fungal foot infection
Eligibility Criteria
Inclusion Criteria: The patient was diagnosed with a fungal foot infection based on the clinical presentation and a positive result from a microscopic examination for fungus. The patient must not have received any prior antifungal therapy, including topical, oral, or intravenous routes, within 36 weeks prior to recruitment. Exclusion Criteria: Patients with conditions other than fungal foot infections, such as bacterial infections or inflammation of the skin on the foot Patients with other fungal diseases that require treatment with systemic antifungals, such as onychomycosis or tinea capitis Patients who are currently taking immunosuppressants or are immunocompromised. Patients who have difficulty applying the medication by themselves. Patients who have been treated for fungal foot infection using methods that are not included in the research protocol.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Active Comparator
Whitfield solution
Zinc oxide nanoparticles solution
Combined Whitfield and Zinc oxide nanoparticles solution
The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
The patient will receive 60 mL of combined Whitfield and 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.